Disclosures for "Efficacy of EP102 (Oral Fospropofol) for the Acute Treatment of Migraine in an Open-label Proof-of-concept Trial: Effect of Time to Treatment"
-
Dr. Heller has received personal compensation in the range of $500,000-$999,999 for serving as a Consultant for Epalex Corporation. Dr. Heller has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Aquestive Therapeutics Inc.. Dr. Heller has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celanese Corporation. Dr. Heller has stock in Epalex Corporation.
-
Ms. Emily has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epalex.
-
Dr. Rogawski has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Xenon Pharmaceuticals.